BioStock: Promore Pharma prepares phase II study

With its drug candidates, Promore Pharma targets two comprehensive patient groups whose access to pharmaceutical products is limited – wound care and scarring. The main project ensereptide is being developed to inhibit scarring, with the aim of initiating a phase IIa study in early 2022. The company's second candidate, ropocamptide, for the stimulation of healing of chronic leg ulcers, is currently undergoing product development for an upcoming phase III study. BioStock talked to Promore Pharma's CEO Jonas Ekblom to learn more.

Read the full interview with Promore Pharma's CEO Jonas Ekblom at biostock.se:

https://www.biostock.se/en/2022/01/promore-pharma-prepares-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se